130 research outputs found
Erratum to “European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel” [Eur. Urol. 79(4) (2021) 480–488, (S0302283820310198), (10.1016/j.eururo.2020.12.033)]
No full textThe publisher regrets that, of the affiliations of the senior author Bas W.G. van Rhijn, only two of the four were shown in the published version of the article. The four correct affiliations, which were also already listed in the original submission to European Urology, now appear above in this erratum. The correct affiliations for author Bas W.G. van Rhijn is updated as above. The publisher would like to apologise for any inconvenience caused
sj-docx-1-ijs-10.1177_10668969221095173 - Supplemental material for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis
No full textSupplemental material, sj-docx-1-ijs-10.1177_10668969221095173 for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis by Laura S. Mertens, Francesco Claps, Roman Mayr, Anjelica Hodgson, Shahrokh F. Shariat, Katrin Hippe, Yann Neuzillet, Joyce Sanders, Maximilian Burger, Damien Pouessel, Wolfgang Otto, Theo H. van der Kwast, Yair Lotan, Yves Allory, Michelle R. Downes and Bas W.G. van Rhijn in International Journal of Surgical Pathology</p
sj-docx-2-ijs-10.1177_10668969221095173 - Supplemental material for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis
No full textSupplemental material, sj-docx-2-ijs-10.1177_10668969221095173 for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis by Laura S. Mertens, Francesco Claps, Roman Mayr, Anjelica Hodgson, Shahrokh F. Shariat, Katrin Hippe, Yann Neuzillet, Joyce Sanders, Maximilian Burger, Damien Pouessel, Wolfgang Otto, Theo H. van der Kwast, Yair Lotan, Yves Allory, Michelle R. Downes and Bas W.G. van Rhijn in International Journal of Surgical Pathology</p
sj-docx-5-ijs-10.1177_10668969221095173 - Supplemental material for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis
No full textSupplemental material, sj-docx-5-ijs-10.1177_10668969221095173 for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis by Laura S. Mertens, Francesco Claps, Roman Mayr, Anjelica Hodgson, Shahrokh F. Shariat, Katrin Hippe, Yann Neuzillet, Joyce Sanders, Maximilian Burger, Damien Pouessel, Wolfgang Otto, Theo H. van der Kwast, Yair Lotan, Yves Allory, Michelle R. Downes and Bas W.G. van Rhijn in International Journal of Surgical Pathology</p
sj-docx-3-ijs-10.1177_10668969221095173 - Supplemental material for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis
No full textSupplemental material, sj-docx-3-ijs-10.1177_10668969221095173 for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis by Laura S. Mertens, Francesco Claps, Roman Mayr, Anjelica Hodgson, Shahrokh F. Shariat, Katrin Hippe, Yann Neuzillet, Joyce Sanders, Maximilian Burger, Damien Pouessel, Wolfgang Otto, Theo H. van der Kwast, Yair Lotan, Yves Allory, Michelle R. Downes and Bas W.G. van Rhijn in International Journal of Surgical Pathology</p
sj-docx-4-ijs-10.1177_10668969221095173 - Supplemental material for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis
No full textSupplemental material, sj-docx-4-ijs-10.1177_10668969221095173 for The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis by Laura S. Mertens, Francesco Claps, Roman Mayr, Anjelica Hodgson, Shahrokh F. Shariat, Katrin Hippe, Yann Neuzillet, Joyce Sanders, Maximilian Burger, Damien Pouessel, Wolfgang Otto, Theo H. van der Kwast, Yair Lotan, Yves Allory, Michelle R. Downes and Bas W.G. van Rhijn in International Journal of Surgical Pathology</p
Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.
No full textThe authors regret that a portion of the supplementary methods did not appear on the online version of this article. This has now been added. There are no errors or changes to the manuscript. The authors would like to apologize for any inconvenience caused.</p
PROSPECTIVE TRIAL TO IDENTIFY OPTIMAL BLADDER CANCER SURVEILLANCE PROTOCOL: REDUCING COSTS WHILE MAXIMIZING SENSITIVITY
No full textLong non-coding RNAs identify a subset of lumina muscle-invasive bladder cancer patients with favorable prognosis
No full textBackground
Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease, and gene expression profiling has identified several molecular subtypes with distinct biological and clinicopathological characteristics. While MIBC subtyping has primarily been based on messenger RNA (mRNA), long non-coding RNAs (lncRNAs) may provide additional resolution.
Methods
LncRNA expression was quantified from microarray data of a MIBC cohort treated with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) (n = 223). Unsupervised consensus clustering of highly variant lncRNAs identified a four-cluster solution, which was characterized using a panel of MIBC biomarkers, regulon activity profiles, gene signatures, and survival analysis. The four-cluster solution was confirmed in The Cancer Genome Atlas (TCGA) cohort (n = 405). A single-sample genomic classifier (GC) was trained using ridge-penalized logistic regression and validated in two independent cohorts (n = 255 and n = 94).
Results
NAC and TCGA cohorts both contained an lncRNA cluster (LC3) with favorable prognosis that was enriched with tumors of the luminal-papillary (LP) subtype. In both cohorts, patients with LP tumors in LC3 (LPL-C3) were younger and had organ-confined, node-negative disease. The LPL-C3 tumors had enhanced FGFR3, SHH, and wild-type p53 pathway activity. In the TCGA cohort, LPL-C3 tumors were enriched for FGFR3 mutations and depleted for TP53 and RB1 mutations. A GC trained to identify these LPL-C3 patients showed robust performance in two validation cohorts.
Conclusions
Using lncRNA expression profiles, we identified a biologically distinct subgroup of luminal-papillary MIBC with a favorable prognosis. These data suggest that lncRNAs provide additional information for higher-resolution subtyping, potentially improving precision patient management
Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer
No full textBackground: bladder cancer is a leading cause of morbidity and mortality. Despite recent advances in understanding its molecular biology, the 5-year survival for muscle-invasive disease (muscle-invasive bladder cancer [MIBC]) remains approximately 50%. Although neoadjuvant chemotherapy (NAC) offers an established 5% absolute survival benefit at 5 years, only the 40% of patients with a major tumor response appear to benefit. There remains, therefore, a critical unmet need for predictive markers to determine which patients are best managed with NAC, as well as for novel targeted therapies to overcome resistance to NAC. Methods: the NAC paradigm offers the optimal clinical context for developing precision therapy for MIBC. Abundant tissue is available for analysis before NAC in all patients and after NAC in patients with residual MIBC. Technologic advances have enabled next-generation sequencing and gene expression microarray analysis of routinely collected and even archived tissue specimens. These technologies provide a foundation for the identification of markers of chemoresistance and for the development of rational cotargeting strategies. Results: modern computational methods allow for some measure of target validation, which can be enhanced by the use of patient-derived primary xenografts (PDX). These PDX can be established at the time of radical cystectomy after NAC if there is residual MIBC. By the time a patient recurs clinically, candidate drugs targeting specific molecular changes in the patient tumor and corresponding PDX would have been tested in the PDX model, and only the most efficacious drug(s) would be administered to the patient. Liquid biopsies in the form of circulating tumor DNA and circulating tumor cells allow noninvasive longitudinal monitoring of the molecular landscape of an advanced tumor as it is being treated with successive courses of systemic therapy. Conclusions: these tools combined form the foundation of an evidence-based precision oncology strategy for MIBC.</p
- …
